184 related articles for article (PubMed ID: 12580116)
1. [Advances in antitumor activity of the hsp90 inhibitor geldanamycin].
Liao ZY; Zhen YS
Yao Xue Xue Bao; 2001 Sep; 36(9):716-20. PubMed ID: 12580116
[No Abstract] [Full Text] [Related]
2. Biosynthesis of the heat-shock protein 90 inhibitor geldanamycin: new insight into the formation of the benzoquinone moiety.
Lee D; Lee K; Cai XF; Dat NT; Boovanahalli SK; Lee M; Shin JC; Kim W; Jeong JK; Lee JS; Lee CH; Lee JH; Hong YS; Lee JJ
Chembiochem; 2006 Feb; 7(2):246-8. PubMed ID: 16381049
[No Abstract] [Full Text] [Related]
3. [Hsp90: how a chaperone becomes a pharmacological target].
Jacquemin-Sablon A
Bull Cancer; 2003 Nov; 90(11):935-6. PubMed ID: 14706894
[No Abstract] [Full Text] [Related]
4. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.
Roe SM; Prodromou C; O'Brien R; Ladbury JE; Piper PW; Pearl LH
J Med Chem; 1999 Jan; 42(2):260-6. PubMed ID: 9925731
[TBL] [Abstract][Full Text] [Related]
5. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
[TBL] [Abstract][Full Text] [Related]
6. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
Ochel HJ; Eichhorn K; Gademann G
Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
[No Abstract] [Full Text] [Related]
7. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
9. Radester, a novel inhibitor of the Hsp90 protein folding machinery.
Shen G; Blagg BS
Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158
[TBL] [Abstract][Full Text] [Related]
10. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
11. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus.
Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS
J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187
[No Abstract] [Full Text] [Related]
12. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
13. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of Hsp90 dimerization modulators.
Chiosis G; Aguirre J; Nicchitta CV
Bioorg Med Chem Lett; 2006 Jul; 16(13):3529-32. PubMed ID: 16621545
[TBL] [Abstract][Full Text] [Related]
15. [Involvement of Hsp90 in the quality control of signal transducing proteins].
Miyata Y
Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):862-6. PubMed ID: 15168480
[No Abstract] [Full Text] [Related]
16. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
19. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
Blagosklonny MV
Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
[TBL] [Abstract][Full Text] [Related]
20. Analysis of hypoxia-inducible factor-1alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry.
Schwock J; Geddie WR; Hedley DW
Cytometry A; 2005 Dec; 68(2):59-70. PubMed ID: 16228978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
